Core Insights - Kestra Medical Technologies reported a strong financial performance for Q2 FY26, achieving a revenue growth of 53% and expanding gross margin to over 50% [2][7] Financial Performance - The company generated revenue of $22.6 million in Q2 FY26, marking a 53% increase compared to the same period last year [7][8] - Gross profit reached $11.4 million, up from $5.8 million in the prior year, with gross margin expanding to 50.6% from 39.6% [8] - GAAP operating expenses were $43.2 million, which included $1.0 million of non-recurring costs, compared to $25.0 million in the prior year [8] - The net loss for Q2 FY26 was $32.8 million, compared to a net loss of $20.6 million in the prior year [8] Operational Highlights - The number of prescriptions written for the ASSURE® system increased by 54% year-over-year, totaling 4,696 prescriptions [8] - Revenue growth was attributed to higher market share, expansion of the wearable defibrillator market, and improvements in revenue cycle management [8] Future Guidance - Kestra has raised its FY26 revenue guidance to $91 million, representing a growth of 52% compared to FY25, up from previous guidance of $88 million [5][7] Cash Position - As of October 31, 2025, the company had cash and cash equivalents totaling $175 million, not including $148 million from a recent equity offering [8]
Kestra Medical Technologies Reports Second Quarter Fiscal 2026 Financial Results